Darbinurad

Darbinurad
Clinical data
Other namesD-0120
Identifiers
  • 2-[1-[[3-(4-cyanophenyl)pyridin-4-yl]sulfanylmethyl]cyclopropyl]acetic acid
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC18H16N2O2S
Molar mass324.40 g·mol−1
3D model (JSmol)
  • C1CC1(CC(=O)O)CSC2=C(C=NC=C2)C3=CC=C(C=C3)C#N
  • InChI=InChI=1S/C18H16N2O2S/c19-10-13-1-3-14(4-2-13)15-11-20-8-5-16(15)23-12-18(6-7-18)9-17(21)22/h1-5,8,11H,6-7,9,12H2,(H,21,22)
  • Key:RHASGUGQMCVYMQ-UHFFFAOYSA-N

Darbinurad is a investigational new drug that is being evaluated for the treatment of gout. It is a selective urate transporter 1 (URAT1) inhibitor that blocks the reabsorption of uric acid within the renal proximal tubule, thereby reducing serum uric acid concentrations.[1][2]

References

  1. ^ Kaufmann D, Chaiyakunapruk N, Schlesinger N (November 2024). "Optimizing gout treatment: A comprehensive review of current and emerging uricosurics". Joint Bone Spine. 92 (2): 105826. doi:10.1016/j.jbspin.2024.105826. PMID 39622367.
  2. ^ "Darbinurad". PatSnap.


This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.